{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T01:03:01Z","timestamp":1788570181721,"version":"build-2803163510"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Outbreaks of macrolide-resistant\n                      <jats:italic>Mycoplasma pneumoniae<\/jats:italic>\n                      (MRMP) in children have posed ongoing treatment challenges. This study aimed to assess the efficacy of doxycycline in treating MRMPP at different time points, offering insights for public health strategies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed children with MRMPP hospitalized between September 2022 and February 2024. They were divided into three main groups based on antibiotic use: (1) those who received azithromycin only (AZI group); (2) those who received doxycycline only (DOX group); (3) those who received azithromycin followed by doxycycline (ATD group), divided into two subgroups according to the duration of azithromycin use: azithromycin use &amp;lt; = 3-day subgroup (ATD1) and azithromycin use &amp;gt; 3-day subgroup (ATD2). Oxygen therapy, electronic bronchoscopy, hormones and gamma globulin were also recorded. Length of hospital stay and duration of fever were used as outcome measures for comparative analyses. Propensity score matching (PSM) analysis was used to adjust the score.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      312 eligible children were identified. The DOX group had the highest 48-h fever reduction rate (80%). The AZI group had a higher proportion of oxygen (77%) and e-bronchoscopy (75%) use, and the ADT group had a higher proportion of hormone use (39%). After adjustment for PSM, oxygen use remained higher in the ATD2 group than in the DOX+ATD1 group (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.026).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Early use of doxycycline in treating MRMPP reduces reliance on adjuvant therapies, thus easing the burden on healthcare resources.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1727627","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T06:36:49Z","timestamp":1770187009000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Timing and efficacy of doxycycline in macrolide-resistant Mycoplasma pneumoniae pneumonia in children: a single-center retrospective study"],"prefix":"10.3389","volume":"14","author":[{"given":"Shaoying","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Pediatrics, West China Second University Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]},{"name":"Key Laboratory of Birth Defects and Related Disease of Women and Children (Sichuan University), Ministry of Education","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, West China Second University Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]},{"name":"Key Laboratory of Birth Defects and Related Disease of Women and Children (Sichuan University), Ministry of Education","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyuan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, West China Second University Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]},{"name":"Key Laboratory of Birth Defects and Related Disease of Women and Children (Sichuan University), Ministry of Education","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e2220949","DOI":"10.1001\/jamanetworkopen.2022.20949","article-title":"Global trends in the proportion of macrolide-resistant Mycoplasma pneumoniae infections: a systematic review and meta-analysis","volume":"5","author":"Kim","year":"2022","journal-title":"JAMA Netw Open."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e515","DOI":"10.1016\/S2666-5247(23)00405-6","article-title":"Resurgence of mycoplasma pneumonia by macrolide-resistant epidemic clones in China","volume":"5","author":"Li","year":"2024","journal-title":"Lancet Microbe."},{"key":"B3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13756-019-0469-7","article-title":"Antimicrobial susceptibility and genotyping of Mycoplasma pneumoniae isolates in Beijing, China, from 2014 to 2016","volume":"8","author":"Zhao","year":"2019","journal-title":"Antimicrob Resist Infect Control."},{"key":"B4","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3390\/microorganisms12010218","article-title":"Novel knowledge of macrolide resistance in Mycoplasma pneumoniae by azithromycin exposure","volume":"12","author":"Oishi","year":"2024","journal-title":"Microorganisms."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1186017","DOI":"10.3389\/fcimb.2023.1186017","article-title":"Novel mechanisms of macrolide resistance revealed by in vitro selection and genome analysis in Mycoplasma pneumoniae","volume":"13","author":"Wang","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.3201\/eid2607.200017","article-title":"Macrolide-resistant Mycoplasma pneumoniae infections in pediatric community-acquired pneumonia","volume":"26","author":"Chen","year":"2020","journal-title":"Emerg Infect Dis."},{"key":"B7","unstructured":"2025"},{"key":"B8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jiac.2020.08.006","article-title":"Epidemiology of macrolide-resistant Mycoplasma pneumoniae by age distribution in Japan","volume":"27","author":"Kawakami","year":"2021","journal-title":"J Infect Chemother."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1186\/s12879-021-06508-7","article-title":"Efficacy of tetracyclines and fluoroquinolones for the treatment of macrolide-refractory Mycoplasma pneumoniae pneumonia in children: a systematic review and meta-analysis","volume":"21","author":"Ahn","year":"2021","journal-title":"BMC Infect Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1001\/jama.2024.6096","article-title":"Low-dose corticosteroids for critically ill adults with severe pulmonary infections: a review","volume":"332","author":"Pirracchio","year":"2024","journal-title":"JAMA."},{"key":"B11","doi-asserted-by":"publisher","first-page":"897550","DOI":"10.3389\/fsurg.2022.897550","article-title":"Pediatric critical illness score, clinical characteristics and comprehensive treatment of children with severe Mycoplasma pneumoniae pneumonia","volume":"9","author":"Fang","year":"2022","journal-title":"Front Surg."},{"key":"B12","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12879-021-05830-4","article-title":"Clinical characteristics of refractory Mycoplasma pneumoniae pneumonia in children treated with glucocorticoid pulse therapy","volume":"21","author":"Zhu","year":"2021","journal-title":"BMC Infect Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.jmii.2020.10.002","article-title":"Rational stepwise approach for Mycoplasma pneumoniae pneumonia in children","volume":"54","author":"Tsai","year":"2021","journal-title":"J Microbiol Immunol Infect."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.4187\/respcare.03032","article-title":"Effects of bronchoalveolar lavage on refractory Mycoplasma pneumoniae pneumonia","volume":"59","author":"Zhang","year":"2014","journal-title":"Respir Care."},{"key":"B15","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1186\/s12879-023-08619-9","article-title":"Optimization strategy for the early timing of bronchoalveolar lavage treatment for children with severe Mycoplasma pneumoniae pneumonia","volume":"23","author":"Wu","year":"2023","journal-title":"BMC Infect Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13052-023-01491-y","article-title":"Acetylcysteine and budesonide for the treatment of refractory Mycoplasma pneumoniae pneumonia in children: a clinical observation","volume":"49","author":"Wang","year":"2023","journal-title":"Ital J Pediatr."},{"key":"B17","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1186\/s12879-020-05270-6","article-title":"Identify clinical factors related to Mycoplasma pneumoniae pneumonia with hypoxia in children","volume":"20","author":"Ling","year":"2020","journal-title":"BMC Infect Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.15586\/aei.v50i1.476","article-title":"Association of Mycoplasma pneumoniae coinfection with adenovirus pneumonia severity in children","volume":"50","author":"Wei","year":"2022","journal-title":"Allergol Immunopathol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/14787210.2018.1414599","article-title":"Antimicrobial therapy of macrolide-resistant Mycoplasma pneumoniae pneumonia in children","volume":"16","author":"Lee","year":"2018","journal-title":"Expert Rev Anti Infect Ther."},{"key":"B20","first-page":"250046","article-title":"Mycoplasma pneumoniae respiratory tract infections in children: when and how to diagnose and treat","volume-title":"Breathe.","author":"Sharplin","year":"2025"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1727627\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T06:36:50Z","timestamp":1770187010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1727627\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":20,"alternative-id":["10.3389\/fpubh.2026.1727627"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1727627","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"article-number":"1727627"}}